Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, placebo-controlled, randomized, Phase 3 trial in
subjects with unresectable stage III non-small cell lung cancer (NSCLC) who have demonstrated
either stable disease or objective response following primary concurrent chemo-radiotherapy
(CRT), comparing overall survival (OS) time in subjects treated with tecemotide versus
subjects treated with tecemotide-matching placebo.